Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinsonâ€™s disease. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Waltham, MA.
Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!